Bal Pharma Limited has issued a postal ballot notice dated January 8, 2026, seeking shareholder approval for the appointment of Dr. Mukesh Beekamchand as Independent Director, following the company's earlier announcement of his appointment and strong Q2 financial performance.

Postal Ballot Process Details

The company has initiated the postal ballot process exclusively through electronic voting, with no physical ballot forms being distributed to shareholders. The e-voting period is scheduled as follows:

National Securities Depository Limited (NSDL) will facilitate the electronic voting process, with Mr. Parameshwar Bhat, Practising Company Secretary from Bangalore, appointed as the Scrutinizer to ensure fair and transparent conduct.

Director Appointment Details

The postal ballot seeks approval for Dr. Mukesh Beekamchand's appointment as Non-Executive Independent Director for a five-year term until February 6, 2031. Key details of the appointment include:

Dr. Mukesh was initially appointed as Additional Director by the Board on November 12, 2025, based on the Nomination and Remuneration Committee's recommendation. He has been appointed to the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective November 29, 2025.

Recent Financial Performance

Prior to this postal ballot announcement, Bal Pharma reported its Q2 financial results showing mixed performance:

For the half-year ended September 30, 2025, the company achieved revenue from operations of ₹13,938.46 lakhs with net profit of ₹110.48 lakhs.

Voting Process and Compliance

Shareholders can participate in the e-voting process through NSDL's platform at www.evoting.nsdl.com . The company has ensured compliance with Section 110 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The postal ballot notice and related documents are available on the company's website at www.balpharma.com and stock exchange websites. Voting rights will be determined based on shareholding as on the cut-off date of January 8, 2026.

The appointment of Dr. Mukesh Beekamchand is expected to strengthen the company's research and development capabilities, particularly given his extensive experience in pharmaceutical research and commercialization spanning over 25 years.

Bal Pharma Limited, a pharmaceutical company, has postponed its decision on the proposed merger of its subsidiary, Lifezen Healthcare Pvt Ltd, with the parent company. The deferment comes as a result of insufficient information available to the Board of Directors during their recent meeting.

Board Meeting Outcome

The company's Board of Directors convened to discuss several agenda items, including the potential merger. However, when it came to the merger proposal, the board found the available data inadequate for making an informed decision. As a result, they have instructed the management to re-present the proposal with all necessary details.

Timeline of Events

To provide a clear picture of the sequence of events, here's a breakdown:

Implications and Next Steps

The deferment of the merger decision highlights the company's commitment to thorough evaluation before making significant corporate decisions. By requesting more comprehensive data, the Board of Directors demonstrates a cautious approach to potential structural changes within the organization.

Investors and stakeholders will likely be watching closely for any updates on this matter. The company is expected to present a more detailed proposal in a future board meeting, although no specific timeline has been provided for when this re-presentation might occur.

It's worth noting that while the merger was initially included as an agenda item, the board's decision to postpone rather than reject outright suggests that the proposal may still be under consideration, pending more complete information.

As this situation develops, shareholders and market observers will be keen to understand the potential impacts of the proposed merger on Bal Pharma's operations, financial structure, and overall strategy. The market's reaction to this deferment and any subsequent announcements will be important indicators of investor sentiment towards the company's corporate actions.

Bal Pharma Limited continues to operate as usual, with its subsidiary Lifezen Healthcare Pvt Ltd remaining a separate entity for the time being. Further updates on this matter are anticipated as the company prepares a more comprehensive merger proposal for future consideration.